$1.80
0.020.84%
At Close: -
$1.79
-0.01-0.56%
After Hours: 7:29 AM EDT
15 minutes delayed
Comments
Loading...
ProQR Therapeutics
PRQRNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
ProQR Therapeutics (NASDAQ:PRQR) Stock, Analyst Ratings, Price Targets, Forecasts
ProQR Therapeutics NV has a consensus price target of $4 based on the ratings of 6 analysts. The high is $6 issued by JMP Securities on May 17, 2023. The low is $2 issued by Citigroup on April 18, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Chardan Capital, and Citigroup on May 10, 2024, May 10, 2024, and April 18, 2024, respectively. With an average price target of $3.17 between HC Wainwright & Co., Chardan Capital, and Citigroup, there's an implied 76.91% upside for ProQR Therapeutics NV from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Chardan Capital
Citigroup
Raymond James
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for ProQR Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/10/2024 | Buy Now | 179.33% | HC Wainwright & Co. | Andrew Fein | → $5 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 39.66% | Chardan Capital | Keay Nakae | $2.5 → $2.5 | Maintains | Buy | Get Alert |
| 04/18/2024 | Buy Now | 11.73% | Citigroup | Yigal Nochomovitz | $1.8 → $2 | Maintains | Neutral | Get Alert |
| 03/14/2024 | Buy Now | 179.33% | HC Wainwright & Co. | Andrew Fein | → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | Buy Now | 39.66% | Chardan Capital | Keay Nakae | $2 → $2.5 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | 123.46% | Raymond James | Steven Seedhouse | $5 → $4 | Maintains | Outperform | Get Alert |
| 11/08/2023 | Buy Now | 11.73% | Chardan Capital | Keay Nakae | → $2 | Upgrade | Neutral → Buy | Get Alert |
| 09/18/2023 | Buy Now | 0.56% | Citigroup | Yigal Nochomovitz | $2.1 → $1.8 | Maintains | Neutral | Get Alert |
| 08/07/2023 | Buy Now | 179.33% | HC Wainwright & Co. | Andrew Fein | → $5 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | Buy Now | 11.73% | Chardan Capital | Keay Nakae | → $2 | Reiterates | Neutral → Neutral | Get Alert |
| 05/26/2023 | Buy Now | 17.32% | Citigroup | Yigal Nochomovitz | $2.25 → $2.1 | Maintains | Neutral | Get Alert |
| 05/17/2023 | Buy Now | 151.4% | Cantor Fitzgerald | Jennifer Kim | $5 → $4.5 | Maintains | Overweight | Get Alert |
| 05/17/2023 | Buy Now | 235.2% | JMP Securities | Jonathan Wolleben | → $6 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/17/2023 | Buy Now | 179.33% | HC Wainwright & Co. | Andrew Fein | → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/30/2023 | Buy Now | 235.2% | JMP Securities | Jonathan Wolleben | → $6 | Reiterates | → Market Outperform | Get Alert |
| 03/30/2023 | Buy Now | 179.33% | HC Wainwright & Co. | Andrew Fein | $1.5 → $5 | Maintains | Buy | Get Alert |
| 12/23/2022 | Buy Now | 179.33% | Raymond James | Steven Seedhouse | $2 → $5 | Maintains | Outperform | Get Alert |
| 12/22/2022 | Buy Now | 179.33% | Cantor Fitzgerald | Jennifer Kim | $0.8 → $5 | Upgrade | Neutral → Overweight | Get Alert |
| 08/15/2022 | Buy Now | -16.2% | HC Wainwright & Co. | Andrew Fein | $2 → $1.5 | Maintains | Buy | Get Alert |
| 08/12/2022 | Buy Now | — | Chardan Capital | Keay Nakae | — | Downgrade | Buy → Neutral | Get Alert |
| 08/12/2022 | Buy Now | 11.73% | Raymond James | Steven Seedhouse | → $2 | Upgrade | Market Perform → Outperform | Get Alert |
| 05/09/2022 | Buy Now | 11.73% | HC Wainwright & Co. | Andrew Fein | $4 → $2 | Maintains | Buy | Get Alert |
| 05/06/2022 | Buy Now | 11.73% | Chardan Capital | Keay Nakae | $2.5 → $2 | Maintains | Buy | Get Alert |
| 04/14/2022 | Buy Now | 39.66% | Chardan Capital | Keay Nakae | $8 → $2.5 | Maintains | Buy | Get Alert |
| 04/14/2022 | Buy Now | 179.33% | JMP Securities | Jonathan Wolleben | $8 → $5 | Maintains | Market Outperform | Get Alert |
| 02/14/2022 | Buy Now | 346.93% | Chardan Capital | Keay Nakae | $18 → $8 | Maintains | Buy | Get Alert |
| 02/14/2022 | Buy Now | 346.93% | JMP Securities | Jonathan Wolleben | $29 → $8 | Maintains | Market Outperform | Get Alert |
| 02/14/2022 | Buy Now | 123.46% | HC Wainwright & Co. | Andrew Fein | $20 → $4 | Maintains | Buy | Get Alert |
| 02/14/2022 | Buy Now | — | Raymond James | Steven Seedhouse | — | Downgrade | Strong Buy → Market Perform | Get Alert |
| 02/01/2022 | Buy Now | 961.45% | Raymond James | Steven Seedhouse | → $19 | Initiates | → Strong Buy | Get Alert |
| 08/09/2021 | Buy Now | 905.59% | Chardan Capital | Keay Nakae | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for ProQR Therapeutics (PRQR) stock?
The latest price target for ProQR Therapeutics (NASDAQ:PRQR) was reported by HC Wainwright & Co. on May 10, 2024. The analyst firm set a price target for $5.00 expecting PRQR to rise to within 12 months (a possible 179.33% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ProQR Therapeutics (PRQR)?
The latest analyst rating for ProQR Therapeutics (NASDAQ:PRQR) was provided by HC Wainwright & Co., and ProQR Therapeutics reiterated their buy rating.
When was the last upgrade for ProQR Therapeutics (PRQR)?
The last upgrade for ProQR Therapeutics NV happened on November 8, 2023 when Chardan Capital raised their price target to $2. Chardan Capital previously had a neutral for ProQR Therapeutics NV.
When was the last downgrade for ProQR Therapeutics (PRQR)?
The last downgrade for ProQR Therapeutics NV happened on August 12, 2022 when Chardan Capital changed their price target from N/A to N/A for ProQR Therapeutics NV.
When is the next analyst rating going to be posted or updated for ProQR Therapeutics (PRQR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProQR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProQR Therapeutics was filed on May 10, 2024 so you should expect the next rating to be made available sometime around May 10, 2025.
Is the Analyst Rating ProQR Therapeutics (PRQR) correct?
While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a reiterated with a price target of $5.00 to $5.00. The current price ProQR Therapeutics (PRQR) is trading at is $1.79, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.